Merix unveils new over-the-counter genital herpes treatment
BARRINGTON, Ill. Merix Pharmaceutical unveiled its new Fast-Results! genital herpes treatment this month while attending the ECRM Cough, Cold and Allergy conference in Dallas.
The only OTC treatment for genital herpes, Fast-Results! answers an unmet need of people who suffer painful symptoms associated with genital herpes outbreaks. Designed to be used in conjunction with prescription medication, Fast-Results! also brings needed treatment to consumers who cannot afford prescription medication.
Fast-Results! genital herpes treatment is comprised of Merix’ patented technology Viracea, which contains an approved ingredient under the FDA OTC antiseptic/antimicrobial monograph, the company stated. At clinical trial, Viracea was shown to be effective in lesions caused by herpes.
According to Centers for Disease Control and Prevention, 16% of Americans currently suffer from genital herpes, which equates to approximately 37 million adults.
“We believe there is a very strong market need for this product,” stated Merix CEO Meryl Squires. Several major retailers have already committed to carrying Fast-Results! genital herpes treatment, Squires said. CVS will begin stocking in mid-May, soon thereafter followed by Rite Aid.
Waterpik expands product offerings with SinuSense
FORT COLLINS, Colo. Perhaps best known for its dental water jet systems, Waterpik recently made a foray into nasal irrigation solutions with a family of products under the Waterpik SinuSense banner. Sinus washing is a natural daily routine to keep sinus passages clear of congestion, allergens and everyday debris, reducing the risk of cold and allergy symptoms.
The four new products — the Water Pulsator, squeeze bottle, neti bottle and neti pot — each feature ergonomic designs and softer spouts for better nose comfort. They are also all BPA free and include a flow control feature.
Waterpik’s Soothing Saline solution contains a blend of saline salts with added aloe vera extract and eucalyptus oil for their moisturizing and antibacterial benefits.
Sanofi-Aventis completes acquisition of Chattem
PARIS A leading global pharmaceutical company has completed its acquisition of a consumer healthcare products manufacturer.
Sanofi-Aventis said that Chattem Inc. officially has become a a wholly-owned subsidiary of the Sanofi-Aventis Group, strengthening its presence in the U.S. consumer healthcare market.
Sanofi-Aventis completed its tender offer of Chattem last month. There also has been speculation that the company is looking to make a stake in the OTC market with other acquisitions. Sanofi-Aventis said Thursday that the acquisition provides new channels for maximizing the potential of converting Sanofi-Aventis’ prescription medicines to over-the-counter products.
Chattem, Sanofi-Aventis’ U.S. consumer healthcare division, will be headquartered in Chattanooga, Tenn. and led by current Chattem CEO Zan Guerry. Guerry will lead the U.S. consumer healthcare business reporting to Greg Irace, president and CEO, Sanofi-Aventis U.S.
“The addition of Chattem to our worldwide portfolio of leading consumer healthcare businesses represents an important milestone in Sanofi-Aventis’ strategy to become a global diversified healthcare leader,” said Christopher Viehbacher, Sanofi-Aventis CEO. “Chattem’s existing sales, marketing and distribution teams and infrastructure provide a tremendous platform for future conversions of prescription medicines to OTC products in the U.S., and I am confident that Chattem will maximize the success of those conversions. I look forward to working with Zan Guerry and the Chattem leadership team, who will play a key role in the performance of our consumer healthcare activities.”